AR073848A1 - Utilizacion de la 4-(3-(hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida para la obtencion de medicamentos destinados al tratamiento de los trastornos del sueno. composicion farmaceutica. - Google Patents
Utilizacion de la 4-(3-(hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida para la obtencion de medicamentos destinados al tratamiento de los trastornos del sueno. composicion farmaceutica.Info
- Publication number
- AR073848A1 AR073848A1 ARP090103933A ARP090103933A AR073848A1 AR 073848 A1 AR073848 A1 AR 073848A1 AR P090103933 A ARP090103933 A AR P090103933A AR P090103933 A ARP090103933 A AR P090103933A AR 073848 A1 AR073848 A1 AR 073848A1
- Authority
- AR
- Argentina
- Prior art keywords
- benzamide
- treatment
- propoxy
- disorders
- hexahydrociclopenta
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000002689 soil Substances 0.000 title 1
- 208000019116 sleep disease Diseases 0.000 abstract 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 2
- MRNMYWNBLVJWKG-UHFFFAOYSA-N 4-[3-(3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl)propoxy]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1OCCCN1CC2CCCC2C1 MRNMYWNBLVJWKG-UHFFFAOYSA-N 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 206010041349 Somnolence Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 150000003891 oxalate salts Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Utilizacion de la 4-{3-[hexadihidrociclopenta[c]pirrol-2-(1H)-il]propoxi}benzamida para la obtencion de medicamentos destinados al tratamiento de los trastornos el sueno. Reivindicacion 5: Composiciones farmacéuticas que contienen 4-{3-[hexadihidrociclopenta[c]pirrol-2-(1H)-il]propoxi}benzamida, o una de sus sales de adicion a un ácido o a una base farmacéuticamente aceptable, en combinacion con uno o varios excipientes farmacéuticamente aceptables, utiles para el tratamiento de los trastornos del sueno que son la narcolepsia, las hipersomnias que aparecen durante el síndrome de apnea obstructiva del sueno o el síndrome de hiperactividad con déficits atencionales y las somnolencias diurnas, así como el tratamiento de los trastornos del sueno asociados al envejecimiento cerebral, a las enfermedades neurodegenerativas o a los traumatismos craneales. Reivindicacion 8: Composiciones farmacéuticas segun una de las reivindicaciones 5 a 7 caracterizadas porque la 4-{3-[hexahidrociclopenta[c]pirrol-2-(1H)-il]propoxi}benzamida está presente en la forma de un oxalato o de un hidrocloruro.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0805721A FR2937251B1 (fr) | 2008-10-16 | 2008-10-16 | Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073848A1 true AR073848A1 (es) | 2010-12-09 |
Family
ID=40416951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103933A AR073848A1 (es) | 2008-10-16 | 2009-10-14 | Utilizacion de la 4-(3-(hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida para la obtencion de medicamentos destinados al tratamiento de los trastornos del sueno. composicion farmaceutica. |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR073848A1 (es) |
| FR (1) | FR2937251B1 (es) |
| WO (1) | WO2010043787A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2974729B1 (fr) * | 2011-05-02 | 2013-04-19 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| FR2976285B1 (fr) * | 2011-06-08 | 2013-05-24 | Servier Lab | Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent |
| FR2976286B1 (fr) * | 2011-06-08 | 2013-05-24 | Servier Lab | 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent |
| FR2983732B1 (fr) | 2011-12-09 | 2013-11-22 | Servier Lab | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent |
| FR2999179A1 (fr) * | 2012-12-07 | 2014-06-13 | Servier Lab | Procede de synthese d'un sel d'addition a un acide pharmaceutiquement acceptable du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, ainsi que les formes cristallines associees |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2866647B1 (fr) * | 2004-02-20 | 2006-10-27 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2008
- 2008-10-16 FR FR0805721A patent/FR2937251B1/fr not_active Expired - Fee Related
-
2009
- 2009-10-14 AR ARP090103933A patent/AR073848A1/es unknown
- 2009-10-15 WO PCT/FR2009/001208 patent/WO2010043787A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FR2937251B1 (fr) | 2011-03-18 |
| FR2937251A1 (fr) | 2010-04-23 |
| WO2010043787A1 (fr) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7398836B2 (ja) | Ｒ－ケタミンおよびその塩の医薬品としての応用 | |
| AR085219A1 (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc | |
| EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
| MX377802B (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| BR112013004443A8 (pt) | composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas | |
| AR073848A1 (es) | Utilizacion de la 4-(3-(hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida para la obtencion de medicamentos destinados al tratamiento de los trastornos del sueno. composicion farmaceutica. | |
| JP2012504560A5 (es) | ||
| BR112015025804A2 (pt) | derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida | |
| JP2019518732A5 (es) | ||
| JP2020503246A5 (es) | ||
| CY1114400T1 (el) | Θεραπευτικες εφαρμογες των παραγωγων κιναζολινεδιονης | |
| RU2018134262A (ru) | Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar | |
| JP2012526832A5 (es) | ||
| CO7200248A2 (es) | Derivados de etinilo como moduladores de la actividad de los receptores mglur5 | |
| JP2019513755A5 (es) | ||
| NZ601920A (en) | New crystalline form of a cyclopropyl benzamide derivative | |
| EA200801488A1 (ru) | Замещенные фенетиламины, обладающие серотонинергической и/или норэпинефринергической активностью | |
| IL206615A (en) | The History of Pipridine Sulfonamide, the Process for Preparing it, Medicines Containing It, and Their Use in the Preparation of Medication for Treatment | |
| ATE506941T1 (de) | Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon | |
| ES2363252T3 (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento del síndrome de smith megenis. | |
| AR089112A1 (es) | Asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen | |
| PH12015500496A1 (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| MX2015009268A (es) | Isomero de isometepteno. | |
| JP2013541582A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |